Table 2 Summary of preclinical prophylactic prostate cancer tumour challenge studies utilising DNA vaccines
From: DNA vaccination for prostate cancer: key concepts and considerations
| Vaccine/ targeted antigen | Model | Delivery route | Clinical outcome | Ref |
|---|---|---|---|---|
| PSCA/STEAP: pCI-neo-mPSCA and/or pCI-neo-mSTEAP1 (100 μg) prime plus MVA-mPSCA and/or MVA-mSTEAP1 (1X107 pfu) boost | C57 BL/6 | i.m. prime | Significant reduction in tumour volume | [17] |
| TRAMP C-1 | i.p. boost | Significant delay in time to form tumours | ||
| hPSA: phPSA (50 μg) with or without CpG | C57 BL/6 | i.m. with EP | Significant delay in appearance of tumours | [46] |
| TRAMP C-1/hPSA | Significantly prolonged survival | |||
| PSMA/PSCA/STEAP: rAd/PSMA, rAD/PSCA, rAd/STEAP prime (1X108 PFU); TRAMP C-1 pulsed DCs (2X106 cells) boost | C57 BL/6 | i.v. prime | Tumour Growth Significantly delayed | [112] |
| TRAMP C-1 | s.c. boost | |||
| STEAP: mSTEAP DN A (2 μg) prime with: mSTEAP DN A (2 μg) or mSTEAP-VRP (106 IU) boost; or mSTEAP-VRP (106 IU) prime and boost | C57 BL/6 | i.d. (gene gun) | Significantly prolonged survival | [56] |
| TRAMP C-2 | s.c. | Significantly delayed tumour growth |